'In the ideal position': Neuren Pharmaceuticals books profit and looks to second treatment after positive results

'In the ideal position': Neuren Pharmaceuticals books profit and looks to second treatment after positive results
Neuren Pharmaceuticals chief executive Jon Pilcher. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Listed pharmaceutical firm Neuren says it is expecting to earn up to A$150 million in royalties in the US for its groundbreaking treatment for Rett Syndrome. Neuren, listed on the Australian Securities Exchange, posted its half-year result for the six months to June 30 on Tuesday. The New Zealand registered company posted an A$8m (NZ$8.7m) after-tax profit, which was a fall from the prior comparable half of $39.8m. Neuren said on Tuesday it earned royalty income of A$24.3m, an increase from A$3.5m in the first half of the 2023 fi...

More Markets

Ampol to delist from NZX
Markets

Ampol to delist from NZX

Only a handful of shareholders own Ampol shares through the NZX.

Smartpay snaps up assets of failing eftpos provider for $4m
Markets

Smartpay snaps up assets of failing eftpos provider for $4m

It will add 5,000 eftpos terminals to its supply and expand its regional reach in NZ.

Partial takeover target Vital posts small profit
Markets

Partial takeover target Vital posts small profit

The business telco provides services including fibre and mobile.